Literature DB >> 23240673

Molecular pathology of endometrial carcinoma.

Xavier Matias-Guiu1, Jaime Prat.   

Abstract

This review paper discusses the main molecular alterations of endometrial carcinoma, the most common cancer of the female genital tract. Two clinicopathological variants are recognized: the oestrogen-related (type I, endometrioid carcinoma) and the non-oestrogen-related (type II, non-endometrioid carcinoma). Whereas type I shows microsatellite instability and mutations in PTEN, PIK3CA, K-RAS and CTNNB1 (beta-catenin), type II exhibits TP53 mutations and chromosomal instability. Recent investigations regarding the role of non-coding RNA have provided important information regarding tumour progression. Understanding pathogenesis at the molecular level is essential for identifying biomarkers of potential use in targeted therapies.
© 2012 Blackwell Publishing Limited.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23240673     DOI： 10.1111/his.12053

Source DB:  PubMed          Journal:  Histopathology        ISSN： 0309-0167            Impact factor:   5.087


  65 in total

1.  Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.

Authors:  Yaser R Hussein; Britta Weigelt; Douglas A Levine; J Kenneth Schoolmeester; Linda N Dao; Bonnie L Balzer; Georgia Liles; Beth Karlan; Martin Köbel; Cheng-Han Lee; Robert A Soslow
Journal:  Mod Pathol       Date:  2014-11-14       Impact factor: 7.842

2.  PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors.

Authors:  Hannah P Yang; Alan Meeker; Richard Guido; Marc J Gunter; Gloria S Huang; Patricia Luhn; Lori d'Ambrosio; Nicolas Wentzensen; Mark E Sherman
Journal:  Cancer Causes Control       Date:  2015-09-16       Impact factor: 2.506

3.  Long non-coding RNA derived miR-205-5p modulates human endometrial cancer by targeting PTEN.

Authors:  Weijuan Xin; Xiaoxia Liu; Jingxin Ding; Jing Zhao; Yang Zhou; Qianyu Wu; Keqin Hua
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

4.  Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis.

Authors:  Amy S Joehlin-Price; Julie A Stephens; Jianying Zhang; Floor J Backes; David E Cohn; Adrian A Suarez
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-18       Impact factor: 4.254

Review 5.  Current status of molecular biomarkers in endometrial cancer.

Authors:  H M J Werner; H B Salvesen
Journal:  Curr Oncol Rep       Date:  2014-09       Impact factor: 5.075

6.  L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition.

Authors:  Mac Versluis; A Plat; M de Bruyn; X Matias-Guiu; J Trovic; C Krakstad; H W Nijman; T Bosse; G H de Bock; H Hollema
Journal:  Virchows Arch       Date:  2018-08-23       Impact factor: 4.064

7.  Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues.

Authors:  George L Mutter; Nicolas M Monte; Donna Neuberg; Alex Ferenczy; Charis Eng
Journal:  Cancer Res       Date:  2014-03-24       Impact factor: 12.701

8.  Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.

Authors:  Kumaravel Mohankumar; Xi Li; Subhashree Sridharan; Keshav Karki; Stephen Safe
Journal:  Gynecol Oncol       Date:  2019-04-30       Impact factor: 5.482

9.  Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping.

Authors:  Yuexin Liu; Russell R Broaddus; Wei Zhang
Journal:  Expert Rev Anticancer Ther       Date:  2014-12-12       Impact factor: 4.512

10.  Estimated intermediate risk endometrial cancer: debate and new perspectives on therapy individualization and prognosis establishment starting from a peculiar case.

Authors:  Salvatore Gizzo; Alberta Fabris; Pietro Litta; Carlo Saccardi
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.